The Forum | World Medical Innovation Forum - Gene and Cell Therapy

The Forum

The World Medical Innovation Forum brings together Mass General Brigham and presenting sponsor Bank of America to advance patient benefiting technologies.

The 2022 Forum explored the promise of new gene and cell therapies, the challenges to their development and investment and market dynamics. GCT is widely recognized as a transformational opportunity in medicine, with the potential to stop or slow the effects of disease by targeting it at the genetic level.

June 12–14, 2023

Gene and cell therapy holds immense potential to advance the quality of patient care, reduce cost, and improve outcomes. Systemic complexity, however, can hinder the translation of breakthroughs to clinical care.

Our collective mission: finding solutions to the medical, operational, and economic challenges confronting GCT-driven care to ensure that patients, providers, and healthcare organizations benefit as soon as possible.

Who Attends

Pharma
Provider
Venture Capital
Medical Device

Investors

Identify new technologies that offer clinical promise. Get insight from clinicians on the medical, technological, and operational factors that drive clinical success. Calibrate your investment strategy with input from industry leaders.

Industry Leaders

Engage with peers from across the GCT and machine learning ecosystem. Meet other executives, decision-makers, and business leaders from health care, pharma, medical devices, and biotech.

Clinicians and Investigators

The one event where physician and clinical leaders connect with peers across the medical landscape. Attend plenary panels, networking events, and fireside chats to capture insight into how GCT and other technology is enhancing the care continuum.

Government Leaders

Join leaders from across the spectrum of government roles. Learn about the priorities of officials who are leading government agencies. 

Payers

Connect with the executives who are determining how gene and cell therapy will be reimbursed.

Attendees by Industry

0%

Life Sciences and Biotech

0%

Healthcare

0%

Gene and Cell Therapy

0%

Clinician, Investigator, Hospital Staff

0%

Venture and Investment

0%

Non-Profit, Government, Media

Gene and Cell Therapy White Papers

2021

With a handful of approvals and a triple digit pipeline, gene and cell therapies (GCT) are on the cusp of ushering in a transformation in therapeutics reminiscent to where we were with antibodies 25 years ago.

This summary is to highlight key issues and opportunities brought up by GCT leaders.

2022

See what nearly two dozen healthcare, scientific and investment experts say are the key issues and opportunities in gene and cell therapy. The World Medical Innovation Forum and Recon Strategy teams have prepared a paper describing what’s ahead for these potentially game-changing discoveries.

The Difference

Why You Need to Be a Part
There are a lot of health conferences out there. But how do you discern what’s a worthy one; what makes the Forum the one you should attend? Let us tell you.

Past Forums

The Forum has hosted many top-tier speakers since its inception. See the past keynoters, as well as access to videos of the panels.

2022 Steering Committee

Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BH; Harvey W. Cushing Professor of Neurosurgery, HMS (2022 Co-Chair) 

Susan Slaugenhaupt, PhD, Scientific Director, Mass General Research Institute, MGH; Professor, Neurology, HMS (2022 Co-Chair)

Ravi Thadhani, MD, CAO, Mass General Brigham; Professor of Medicine and Faculty Dean for Academic Programs, HMS (2022 Co-Chair)

Bob Carter, MD, PhD, Chairman, Department of Neurosurgery, MGH; William and Elizabeth Sweet Professor of Neurosurgery, HMS

Lawrence Di Rita, Global Public Policy & Environmental Strategy, President, Greater Washington, DC, Bank of America

Florian Eichler, MD, Director, Center for Rare Neurological Diseases, MGH; Associate Professor of Neurology, HMS

Meredith Fisher, PhD, Partner, Mass General Brigham Ventures

Jean-François Formela, MD, Partner, Atlas Venture

Pat Fortune, PhD, VP, Strategic Innovation Leader, Mass General Brigham Innovation

Anna Greka, MD, PhD, Associate Professor of Medicine, BWH, HMS; Director, Kidney Disease Initiative, Broad Institute of MIT and Harvard

Reid Huber, PhD, Partner, Third Rock Ventures

Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor of Neurology & Neuroscience, HMS

J. Keith Joung, MD, PhD, Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH; Professor of Pathology, HMS

Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences

Elizabeth Everett Krisberg, Head of Bank of America Institute

John Lepore, MD, SVP, Head of Research, GlaxoSmithKline

Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH; Associate Professor, Medicine, HMS

Marie McDonnell, MD, Chief, Diabetes Section and Director, Diabetes Program, BWH; Lecturer, HMS

Adrian Mee, Head of Global Healthcare Investment Banking, and Chairman, Global M&A, BofA Securities

Patricia Musolino, MD, PhD, Co-Director Pediatric Cerebrovascular Service, MGH; Assistant of Neurology, HMS

Chandra Ramanathan, PhD, Global Head, Pharma R&D Open Innovation, Bayer

Alfred Sandrock, MD, PhD, CEO, Voyager Therapeutics 

Bastiano Sanna, PhD, Executive Vice President, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals

Christine Seidman, MD, Director, Cardiovascular Genetics Center, BWH; Thomas W. Smith Professor of Medicine and Genetics, HMS

Angela Shen, MD, VP, Strategic Innovation Leader, Mass General Brigham Innovation

Deb Sloan, CFA, SVP, Treasury, Mass General Brigham